Investors & Media

Daniella Beckman has served on our Board of Directors since December 2021 and is Chair of the Audit Committee. Since 2019, Ms. Beckman has served as Chief Financial Officer of Tango Therapeutics, where she oversees finance, investor relations and business development. Prior to joining Tango, Ms. Beckman provided consulting services and served as Interim Chief Financial Officer for early-stage biotechnology companies from 2015 to 2019. Previously, Ms. Beckman was Chief Financial Officer of Idenix Pharmaceuticals, where she was responsible for finance, investor relations and information technology until the company was acquired by Merck in 2014. Earlier in her career, she held various finance positions at Coley Pharmaceutical Group, Biogen and PricewaterhouseCoopers. Ms. Beckman also serves as Chair of the Audit Committee and member of the Compensation Committee for the Board of Directors of Vor Biopharma. She previously served as Chair of the Audit Committee and member of the Nomination and Governance Committee for the Board of Directors of 5:01 Acquisition Corp. and Chair of both the Audit and the Nomination and Governance Committees for the Board of Directors of Translate Bio. Ms. Beckman received a B.A. in business administration and accounting from Boston University.